Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI106637

Studies of human sera with cytotoxic activity

Ralph C. Williams Jr., Jean D. Emmons, and Edmond J. Yunis

Arthritis Unit, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, 87106

Department of Laboratory Medicine, University of Minnesota Hospitals, Minneapolis, Minnesota, 55455

Find articles by Williams, R. in: PubMed | Google Scholar

Arthritis Unit, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, 87106

Department of Laboratory Medicine, University of Minnesota Hospitals, Minneapolis, Minnesota, 55455

Find articles by Emmons, J. in: PubMed | Google Scholar

Arthritis Unit, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, 87106

Department of Laboratory Medicine, University of Minnesota Hospitals, Minneapolis, Minnesota, 55455

Find articles by Yunis, E. in: PubMed | Google Scholar

Published July 1, 1971 - More info

Published in Volume 50, Issue 7 on July 1, 1971
J Clin Invest. 1971;50(7):1514–1524. https://doi.org/10.1172/JCI106637.
© 1971 The American Society for Clinical Investigation
Published July 1, 1971 - Version history
View PDF
Abstract

42 human sera showing in vitro cytotoxic activity of restricted or broad HL-A specificities with test human lymphocytes were studied for the molecular and immunoglobulin class of cytotoxic antibody using sucrose gradient separations, DEAE-cellulose chromatography, and Sephadex G-200 gel filtration. Sera originated from patients with previous multiple pregnancies (19), multiply transfused patients (8), subacute bacterial endocarditis (4), systemic lupus (2), and human umbilical cord sera (9). In 32 of 42 instances, predominant cytotoxic activity was found in high molecular weight gradient fractions; however, DEAE chromatographic separations revealed cytotoxic activity in initial buffer fractions containing primarily γG globulin. Gradient separations of cytotoxic activity within initial γG DEAE fractions showed localization of cytotoxicity only in high molecular weight materials. Confirmation of high molecular weight γG cytotoxic activity was obtained by resistance to mercaptoethanol treatment, abolition of activity after absorption only with specific anti-γG antisera, and by the finding that high molecular weight cytotoxic activity in gradients or gel filtration run at neutral pH 7.4 became 7S when separations were rerun at an acidic pH of 4.0. Such 7S activity again became rapidly sedimenting when the same fractions were again rerun in gradients at neutral pH.

19S γM cytotoxic activity was documented in a panel of 15 human sera containing anti-“I” cold agglutinins. In this instance the cytotoxic activity appeared to be related to the cold agglutinin antibody since it was mercaptoethanol sensitive and could be demonstrated in monoclonal antibody eluates containing primarily γM.

No in vitro protection again cytotoxic effect was demonstrated when isolated human 19S anti-γ-globulins were aded to the lymphocytotoxic assay system.

With the exception of cold agglutinins, human cytotoxic antibodies appear to be primarily γG producing in vitro lymphocyte killing either as 7S γG globulin or as rapidly sedimenting aggregates or complexes of γG molecules.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1514
page 1514
icon of scanned page 1515
page 1515
icon of scanned page 1516
page 1516
icon of scanned page 1517
page 1517
icon of scanned page 1518
page 1518
icon of scanned page 1519
page 1519
icon of scanned page 1520
page 1520
icon of scanned page 1521
page 1521
icon of scanned page 1522
page 1522
icon of scanned page 1523
page 1523
icon of scanned page 1524
page 1524
Version history
  • Version 1 (July 1, 1971): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts